RT Journal Article
SR Electronic
T1 Results from Canton Grisons of Switzerland Suggest Repetitive Testing Reduces SARS-CoV-2 Incidence (February-March 2021)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21259739
DO 10.1101/2021.07.13.21259739
A1 Gorji, Hossein
A1 Lunati, Ivan
A1 Rudolf, Fabian
A1 Vidondo, Beatriz
A1 Hardt, Wolf-Dietrich
A1 Jenny, Patrick
A1 Engel, Doortje
A1 Schneider, Jörg
A1 Jamnicki, Marina
A1 Leuthold, Rudolf
A1 Risch, Lorenz
A1 Risch, Martin
A1 Bühler, Martin
A1 Sommer, Adrian
A1 Caduff, Alexa
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.13.21259739.abstract
AB In February 2021, in response to emergence of more transmissible SARS-CoV-2 virus variants, the Canton Grisons launched a unique RNA mass testing program targeting the labour force in local businesses. Employees were offered weekly tests free of charge and on a voluntary basis. If tested positive, they were required to self-isolate for ten days and their contacts were subjected to daily testing at work. Thereby, the quarantine of contact persons could be waved. Here, we evaluate the effects of the testing program on the tested cohorts. We examined 121’364 test results from 27’514 participants during February-March 2021. By distinguishing different cohorts of employees, we observe a noticeable decrease in the test positivity rate and a statistically significant reduction in the associated incidence rate over the considered period. The reduction in the latter ranges between 18%-50%. The variability is partly explained by different exposures to exogenous infection sources (e.g., contacts with visiting tourists or cross-border commuters). Our analysis provides the first empirical evidence that applying repetitive mass testing to a real population over an extended period of time can prevent spread of COVID-19 pandemic. However, to overcome logistic, uptake, and adherence challenges it is important that the program is carefully designed and that disease incursion from the population outside of the program is considered and controlled.Competing Interest StatementLorenz Risch and Martin Risch are key shareholders in Risch laboratories, which provided the laboratory testing.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Cantonal Research Ethics Commission of Zurich Switzerland (KEK-ZH), and obtaining ethical approval was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source data set is available on https://www.gr.ch/DE/institutionen/verwaltung/djsg/ga/coronavirus/info/medien/Seiten/Medien.aspx. The analysis was implemented with R. The corresponding codes are available upon request from the corresponding author. https://www.gr.ch/DE/institutionen/verwaltung/djsg/ga/coronavirus/info/medien/Seiten/Medien.aspx